The clinical evaluation of HER-2 status: which test to use?
about
c-myc, not her-2/neu, can predict the prognosis of breast cancer patients: how novel, how accurate, and how significant?Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesRepresentational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variationHER2 testing: a review of detection methodologies and their clinical performanceBreast cancer evaluation by fluorescent dot detection using combined mathematical morphology and multifractal techniquesA simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples.Optical fiber-based in vivo quantification of growth factor receptors.The epidermal growth factor receptor family in breast cancer.Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.Best Practice No 176: Updated recommendations for HER2 testing in the UKIHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysisReal-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis.Testing for HER2 in breast cancer.External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.Differentiation between genetic mutations of breast cancer by breath volatolomics.Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours.Benefits, issues, and recommendations for personalized medicine in oncology in CanadaRole of Cyclooxygenase 2 (COX-2) in Prognosis of Breast Cancer.Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer.Cytogenetic testing for therapeutic indication in cancer.Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic vaReal-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.Observer variation in immunohistochemical analysis of protein expression, time for a change?Genetic heterogeneity of HER2 in breast cancer: impact on HER2 testing and its clinicopathologic significance.Real-time PCR quantification of c-erbB-2 gene is an alternative for FISH in the clinical management of breast carcinoma patients.HER2 status in breast cancer--an example of pharmacogenetic testing.Borderline HER‐2 breast cancer cases: Histochemical versus real‐time PCR analysis and impact of different cut‐off values
P2860
Q24803848-1EC84EE5-2726-4447-A530-11F74A2748BCQ26743510-46268549-DCF3-4055-BE98-68CA3BCB3CEDQ28207115-DB0C4C18-1A15-48E4-9E08-A9485002A76EQ28280488-D71F6BD2-99F7-479B-B1CE-77A313C46D13Q33871528-620B2F43-A8D4-4EB7-BE53-332787A9ED01Q33919227-ACBA1054-814A-4990-9EE1-98D270A9F000Q34226408-112A8E72-AA58-45A4-A56C-69C009D9337FQ34363400-0C491CB3-BCFD-4C6F-AA80-9FFCF997E217Q35078787-CEC46C6D-6887-463F-B417-8C934183B31CQ35587451-5AA05CAB-625C-465C-906A-3AB7564A26AAQ35588768-4285B6B8-7A6E-464E-8120-043DD0DA282DQ35663809-7547C3CF-EFD0-4DF6-ADCE-95A398990AB5Q35778406-881E62A8-FD93-43DC-AFD6-85DEFFB4F544Q35789663-D0402FE3-293B-468A-B4A4-95BA16305985Q35871999-280F8052-B127-488B-8D6D-58EDB52D4BA9Q36017256-8912234A-A1D8-4514-9CCA-283F0A6C1742Q36689113-A7E21468-94E6-46BE-A97B-903AF071AC41Q37010568-9AC89809-8B58-451F-B9E6-D3866C2ADBB6Q37123529-9B9B4CFE-7EDE-4FD1-873B-F1FDF32BAAD1Q37248023-85E8E1B2-BAF9-474C-B7DE-10647EE39556Q37660357-AEF1152F-3A1B-4067-B306-8F06E24F5AB9Q47261967-E2DA6C9D-3EB0-4449-986D-75F1A2A998E0Q47291002-59E9BFCC-7085-4168-B54F-F72B6FFFBB68Q49545664-62B3D11E-33FC-44B2-A5F8-6E8D108D1E54Q50547552-95E0A622-5BB5-43CF-A3E3-151C8E88248AQ51510677-6E56F0D6-D9C0-4A09-8117-C38D37F236E0Q53004389-A0A9519E-FD6E-4AE0-B614-94CF8578DFB9Q54519232-5AFC8884-F159-4DFA-A7C1-BD77E6F715D1Q54696645-FB602783-A78B-4327-B4B3-6A420E55B927Q55439955-E189B3CF-85CB-422D-A7CE-34F31FECB482Q58005897-55419334-53C5-4EC3-9E8A-F9B975BD2990
P2860
The clinical evaluation of HER-2 status: which test to use?
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The clinical evaluation of HER-2 status: which test to use?
@ast
The clinical evaluation of HER-2 status: which test to use?
@en
type
label
The clinical evaluation of HER-2 status: which test to use?
@ast
The clinical evaluation of HER-2 status: which test to use?
@en
prefLabel
The clinical evaluation of HER-2 status: which test to use?
@ast
The clinical evaluation of HER-2 status: which test to use?
@en
P2093
P2860
P356
P1476
The clinical evaluation of HER-2 status: which test to use?
@en
P2093
Elizabeth Mallon
John Bartlett
P2860
P304
P356
10.1002/PATH.1354
P577
2003-04-01T00:00:00Z